Featured Speakers from Pfizer, ImmunoGen, and more to speak at Protein Discovery Summit
John Lambert, Executive Vice President at ImmunoGen, and Seema Kumar, Principal Scientist at Pfizer & more to speak at GTCBio's Protein Discovery Summit.
- (1888PressRelease) September 21, 2016 - John Lambert, Executive Vice President at ImmunoGen, and Seema Kumar, Principal Scientist at Pfizer, will be giving presentations at the Antibody Drug Conjugates Conference, which is happening on December 5th - 6th, 2016. Meanwhile, John McCafferty, Chief Executive Officer at IONTAS, and Vu Truong, Chief Executive Officer at Aridis Pharmaceuticals will be giving presentations at the Antibody & Protein Therapeutics Conference, which is happening on December 6th - 7th, 2016. These conferences are a part of our Protein Discovery Summit, which will be running from December 5th - 7th, 2016 at the Hyatt Regency in Boston, MA.
John M. Lambert joined ImmunoGen as Senior Director of Research in 1987 and was promoted to Vice President, Research and Development in 1994, to Senior Vice President, Pharmaceutical Development in 2000, to Senior Vice President, Research and Development and Chief Scientific Officer in early 2008, and to Executive Vice President, Research and Development and Chief Scientific Officer in July 2008. In 2014 he was named Distinguished Research Fellow. Prior to his tenure with ImmunoGen, Dr. Lambert was Assistant Professor of Pathology at the Dana-Farber Cancer Institute in Boston, MA. Dr. Lambert received his doctorate in Biochemistry from Cambridge University in England.
Seema Kumar is a Principal Scientist at Pfizer. She leads a group that provides regulated bioanalytical support including assay development, validation and sample analysis for the pharmacokinetics and immunogenicity assessment for pre-clinical and clinical development of Pfizer's biotherapeutics portfolio. She also provides compliance oversight to Core Automation Team, and is also responsible for technical and compliance oversight of GLP studies outsourced to CROs. Seema earned her Ph.D. in Biophysical Chemistry from Johns Hopkins University. She has authored several publications in peer-reviewed journals and book chapters, and has presented at various national and international conferences and scientific meetings.
John McCafferty is a pioneer and inventor of antibody-phage display and co-founder of Cambridge Antibody Technology. John established a highly proficient proteomics group at the Wellcome Trust Sanger Institute which developed cutting edge protein expression and high throughput recombinant antibody isolation. More recently he has headed a research group within the Department of Biochemistry, University of Cambridge. The focus here was identifying anti-receptor antibodies with therapeutic potential in cancer indications. In 2002, after 12 years in Cambridge Antibody Technology (now MedImmune, a fully owned subsidiary of pharmaceutical giant Astra Zeneca) McCafferty set up a group at the Sanger Institute developing and utilizing methods for protein generation and recombinant antibody isolation in high throughput for proteomic applications. McCafferty has been involved in developing large human antibody repertoires both at CAT and at the Sanger Institute from which antibodies of high affinity and specificity to any antigen can be derived. He ran a laboratory at the Biochemistry Dept at University of Cambridge capitalising on the above technologies with a focus on the study of protein:protein interactions driving direct cell:cell communication and has recently founded a new therapeutic antibody discovery biotechnology company, IONTAS Ltd.
Dr. Truong is a founder of Aridis and recently elected to the CEO position in 2014 after having served as the company's Chief Scientific Officer for the past 9 years. He has over 15 years of experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to Medimmune), and Medimmune (sold to Astra Zeneca). He has a life-long interest and research experience in infectious diseases, focusing on the development of innovative human monoclonal antibodies and vaccines designed to address life threatening infections. His product development experience includes FluMist™, Synagis™ mAb, and a number of other monoclonal antibody based therapeutics. Dr. Truong is the principal architect of the Aridis technologies, which includes a range of anti-infective products and pharmaceutical processing technologies. He received his Ph.D. in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.
The Protein Discovery Summit will answer exciting key questions for the successful development of new drugs and targeted kinase signaling. Join this multi-disciplinary forum and network with colleagues from industry and academia to discuss the methods and tools that will ensure the most efficient and accurate optimization of proteins.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam